Vanda Pharmaceuticals (VNDA) Capital Expenditures Growth (3y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 46.88% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.97% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 16.27% |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 63.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.03% |
| Dec 31, 2025 | -27.07% |
| Sep 30, 2025 | 2.85% |
| Jun 30, 2025 | 15.71% |
| Mar 31, 2025 | 79.81% |
| Dec 31, 2024 | 16.89% |
| Sep 30, 2024 | 162.56% |
| Jun 30, 2024 | -28.70% |
| Mar 31, 2024 | -62.24% |
| Dec 31, 2023 | -36.02% |
| Sep 30, 2023 | -53.96% |
| Jun 30, 2023 | -36.02% |
| Mar 31, 2023 | -48.48% |
| Dec 31, 2022 | 56.97% |
| Sep 30, 2022 | -20.45% |
| Jun 30, 2022 | -9.92% |
| Mar 31, 2022 | -42.43% |
| Dec 31, 2021 | 82.63% |
| Sep 30, 2021 | -27.52% |
| Jun 30, 2021 | 58.39% |
| Mar 31, 2021 | -1.25% |
| Dec 31, 2020 | 71.65% |
| Sep 30, 2020 | -12.80% |
| Jun 30, 2020 | -30.44% |
| Mar 31, 2020 | -7.94% |
| Dec 31, 2019 | -53.96% |
| Sep 30, 2019 | -21.12% |
| Dec 31, 2018 | -68.65% |
| Sep 30, 2018 | -46.21% |
| Jun 30, 2018 | -21.66% |
| Mar 31, 2018 | -44.34% |
| Dec 31, 2017 | -17.33% |
| Sep 30, 2017 | 91.29% |
| Jun 30, 2017 | 36.94% |
| Mar 31, 2017 | 52.42% |
| Dec 31, 2016 | 92.97% |
| Sep 30, 2016 | 340.67% |
| Dec 31, 2015 | 367.23% |
| Sep 30, 2015 | 271.84% |
| Jun 30, 2015 | 1.77% |
| Mar 31, 2015 | -24.85% |
| Dec 31, 2014 | 63.74% |
| Sep 30, 2014 | 15.95% |